Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Endoscopically diagnosed angiodysplasias~* Transfusion dependency: at least 4 red blood cell transfusions (per 500 ml or packed cells) and/or parental iron infusions (per 500 mg) in the year before inclusion~* Failure of endoscopic therapy: at least one endoscopic attempt to coagulate the angiodysplasias or unsuitable for endoscopic procedures~* Providing informed consent~* Older than 18 years~Exclusion Criteria:~* Liver cirrhosis Child-Pugh C, liver failure or diagnosed portal hypertension~* Previous treatment with octreotide for the same indication (refractory anemia due to angiodysplasias)~* Current thalidomide treatment which is effective (no transfusion dependency)~* Life expectancy \< 1 year~* Left ventricular assist devices (LVAD's)~* Hereditary hemorrhagic diseases or hematological disorders with active treatment~* Pregnancy or nursing women~* Uncontrolled diabetes as defined by HbA1C \>64 mmol/ml, despite adequate therapy~* Known hypersensitivity to somatostatin analogs~* Symptomatic cholecystolithiasis~* Systemic cancer under active treatment (chemotherapy or radiation therapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octreotide (Type: ACTIVE_COMPARATOR): Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
- Standard of care (Type: NO_INTERVENTION): Patients receive standard of care without a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).